A Phase 1b/2, Double-Blind, Placebo-Controlled, Randomized, Parallel-Arm Study to Explore the Safety, Pharmacokinetics, and Proof of Biological Activity of DS-7011a in Patients with Systemic Lupus Erythematosus

Daiichi Sankyo Co., Ltd.0 个研究点目标入组 24 人开始时间: 2024年6月12日最近更新: 2025年4月15日

试验速览

暂无简介。

•Male and female subjects must be of 18 years or more with definite SLE for at least 6 months prior to Screening, defined according to the 2019 European League Against Rheumatism (EULAR)/ American College of Rheumatology (ACR) classification criteria for SLE3, including documented history of positivity for antinuclear antibody (titer >=1:80).
•Body mass index (BMI) >=18 kg/m^2 and body weight >=45 kg.
•Presence of active CLE (acute, subacute, and chronic cutaneous lupus) with active skin involvement and a CLASI-A score of 4 or higher at the time of Screening and randomization, as recognized by 2 adjudicators, despite adequate use of conventional therapies (either topical corticosteroids or antimalarial agents used for at least 12 weeks prior to Screening) or because of the requirement to discontinue these therapies due to side effects or poor tolerability.
•Subjects must be willing to have skin tape harvests collected from the affected skin area (skin tape stripping done on the target lesion).
•Subjects must be vaccinated against COVID-19.

•Active LN on induction therapy, or induction therapy completed within 12 weeks prior to Screening.
•Active neuropsychiatric SLE.
•Primary diagnosis of autoimmune or rheumatic disease other than SLE or drug-induced lupus.
•History of chronic, recurrent or recent serious infection, including viral infections, as determined by the investigator, or requiring anti-infective treatment within 12 weeks prior to Screening.
•History of severe herpes infection or signs of herpes or varicella zoster viral infection within 12 weeks prior to Screening.
•Positive COVID-19 molecular (polymerase chain reaction [PCR]) test at Screening or symptoms suggestive of SARS-CoV-2 infection or close contact with an individual with SARS-CoV-2 infection within 2 weeks prior to randomization.

safety and tolerability

未报告次要终点

发起方